Rasna Therapeutics, Inc. (RASP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 210.97 Thousand USD | -3.97% |
| 2022 | 219.68 Thousand USD | -62.89% |
| 2021 | 592 Thousand USD | 13.45% |
| 2020 | 521.84 Thousand USD | 96.99% |
| 2019 | 264.9 Thousand USD | 92.88% |
| 2018 | 137.34 Thousand USD | 0.0% |
| 2017 | - USD | -100.0% |
| 2016 | 8559.00 USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 303.96 Thousand USD | 34.67% |
| 2024 Q1 | 225.7 Thousand USD | 6.98% |
| 2023 Q2 | 220.4 Thousand USD | -2.97% |
| 2023 FY | 210.97 Thousand USD | -3.97% |
| 2023 Q1 | 227.15 Thousand USD | 3.4% |
| 2023 Q4 | 210.97 Thousand USD | -2.1% |
| 2023 Q3 | 215.5 Thousand USD | -2.22% |
| 2022 Q1 | 393.61 Thousand USD | -33.51% |
| 2022 FY | 219.68 Thousand USD | -62.89% |
| 2022 Q4 | 219.68 Thousand USD | 61.52% |
| 2022 Q3 | 136.01 Thousand USD | -72.33% |
| 2022 Q2 | 491.47 Thousand USD | 24.86% |
| 2021 Q1 | 579.41 Thousand USD | 11.03% |
| 2021 FY | 592 Thousand USD | 13.45% |
| 2021 Q3 | 784.23 Thousand USD | 25.41% |
| 2021 Q2 | 625.31 Thousand USD | 7.92% |
| 2021 Q4 | 592 Thousand USD | -24.51% |
| 2020 Q1 | 331.16 Thousand USD | 25.01% |
| 2020 Q4 | 521.84 Thousand USD | 9.82% |
| 2020 FY | 521.84 Thousand USD | 96.99% |
| 2020 Q3 | 475.19 Thousand USD | 4.08% |
| 2020 Q2 | 456.56 Thousand USD | 37.86% |
| 2019 Q2 | 245.48 Thousand USD | 4.46% |
| 2019 Q1 | 235 Thousand USD | 71.11% |
| 2019 Q3 | 257.85 Thousand USD | 5.04% |
| 2019 Q4 | 264.9 Thousand USD | 2.73% |
| 2019 FY | 264.9 Thousand USD | 92.88% |
| 2018 FY | 137.34 Thousand USD | 0.0% |
| 2018 Q4 | 137.34 Thousand USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 FY | - USD | -100.0% |
| 2016 Q4 | - USD | -100.0% |
| 2016 Q2 | 4209.00 USD | -58.88% |
| 2016 Q1 | 10.23 Thousand USD | 0.0% |
| 2016 Q3 | 8559.00 USD | 103.35% |
| 2016 FY | 8559.00 USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 99.488% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 94.882% |
| SQZ Biotechnologies Company | 27.47 Million USD | 99.232% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 99.514% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 99.291% |
| Mesoblast Limited | 118.7 Million USD | 99.822% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | 77.752% |
| Genus plc | 233.1 Million USD | 99.909% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 92.8% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 84.298% |
| Marizyme, Inc. | 18.71 Million USD | 98.873% |
| ContraFect Corporation | 2.88 Million USD | 92.677% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | 71.87% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -55.716% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 85.413% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 90.93% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 96.271% |
| MultiCell Technologies, Inc. | 202.58 USD | -104044.042% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 99.633% |
| EV Biologics, Inc. | 1.49 Million USD | 85.886% |
| Q BioMed Inc. | 4.1 Million USD | 94.867% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 99.363% |
| Neon Bloom, Inc. | 630.07 Thousand USD | 66.516% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 82.825% |
| Biomind Labs Inc. | 735.54 Thousand USD | 71.317% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.877% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 98.377% |
| Skye Bioscience, Inc. | 4.61 Million USD | 95.429% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | 76.243% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -49.08% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 96.407% |
| IMV Inc. | 28.88 Million USD | 99.27% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -720.308% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 90.658% |
| GB Sciences, Inc. | 1.75 Million USD | 88.008% |
| Alpha Cognition Inc. | 1.22 Million USD | 82.712% |
| HST Global, Inc. | 98.31 Thousand USD | -114.582% |
| CSL Limited | 12.18 Billion USD | 99.998% |
| Halberd Corporation | 150 Thousand USD | -40.65% |
| Enzolytics Inc. | 996.33 Thousand USD | 78.825% |
| Resverlogix Corp. | 6.49 Million USD | 96.75% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | 55.817% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | 17.456% |
| argenx SE | 20 Million USD | 98.945% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 99.537% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 92.211% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -1963.325% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.949% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -5.164% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 91.201% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | 7.988% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 99.688% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 93.028% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 41.349% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 98.962% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -41.924% |
| BioStem Technologies, Inc. | 4.71 Million USD | 95.522% |
| ONE Bio Corp. | 19.71 Million USD | 98.93% |
| Reve Technologies, Inc. | 250.18 Thousand USD | 15.671% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | 15.176% |
| Agentix Corp. | 50 Thousand USD | -321.95% |
| LadRx Corporation | 33.6 Thousand USD | -527.79% |
| Cell Source, Inc. | 9.25 Million USD | 97.72% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 72.101% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | 72.101% |
| NovAccess Global Inc. | 2.19 Million USD | 90.41% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 97.017% |
| Itoco Inc. | 228.37 Thousand USD | 7.62% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 95.766% |
| Kadimastem Ltd | 891.22 Thousand USD | 76.328% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 47.499% |
| CytoDyn Inc. | 30.07 Million USD | 99.299% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | 56.436% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | 40.038% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 97.302% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -72.224% |
| Rebus Holdings, Inc. | 310 Thousand USD | 31.944% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 95.545% |
| International Stem Cell Corporation | 4.17 Million USD | 94.95% |
| Bioxytran, Inc. | 1.92 Million USD | 89.04% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -238.031% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 90.326% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 97.463% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 97.543% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 86.437% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | 21.278% |
| Neutra Corp. | 54.15 Thousand USD | -289.569% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 88.471% |
| PureTech Health plc | 25.51 Million USD | 99.173% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 82.767% |
| IXICO plc | 472.02 Thousand USD | 55.304% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 98.639% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 99.661% |
| CSL Limited | 12.18 Billion USD | 99.998% |
| Cellectis S.A. | 92.77 Million USD | 99.773% |